JP4846198B2 - ヒトの出産を容易にするための組成物 - Google Patents
ヒトの出産を容易にするための組成物 Download PDFInfo
- Publication number
- JP4846198B2 JP4846198B2 JP2003565445A JP2003565445A JP4846198B2 JP 4846198 B2 JP4846198 B2 JP 4846198B2 JP 2003565445 A JP2003565445 A JP 2003565445A JP 2003565445 A JP2003565445 A JP 2003565445A JP 4846198 B2 JP4846198 B2 JP 4846198B2
- Authority
- JP
- Japan
- Prior art keywords
- cellulose
- composition
- lubricant
- alkali metal
- polyvinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000000314 lubricant Substances 0.000 claims abstract description 36
- 239000000126 substance Substances 0.000 claims abstract description 32
- 230000035606 childbirth Effects 0.000 claims abstract description 19
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 10
- -1 alkali metal salts Chemical class 0.000 claims description 25
- 230000001050 lubricating effect Effects 0.000 claims description 19
- 239000000499 gel Substances 0.000 claims description 16
- 208000034423 Delivery Diseases 0.000 claims description 14
- 230000009677 vaginal delivery Effects 0.000 claims description 13
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 229920001451 polypropylene glycol Polymers 0.000 claims description 8
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003925 fat Substances 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 125000005341 metaphosphate group Chemical group 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 150000002009 diols Chemical class 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 3
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 3
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 3
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 3
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920001290 polyvinyl ester Polymers 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical class OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 238000013329 compounding Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 210000004381 amniotic fluid Anatomy 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 7
- 210000003754 fetus Anatomy 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000008774 maternal effect Effects 0.000 description 5
- 239000011368 organic material Substances 0.000 description 5
- 230000032696 parturition Effects 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 210000001691 amnion Anatomy 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 229940066363 beractant Drugs 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 108010015964 lucinactant Proteins 0.000 description 3
- 239000003580 lung surfactant Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000034347 Faecal incontinence Diseases 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 210000003903 pelvic floor Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 description 2
- 229960003400 sulprostone Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YQMHOGGOFBFXQZ-ADZFUJRMSA-N (1e)-2-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid;hydrochloride Chemical compound Cl.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C.C=1C=C(Cl)C=CC=1NC(/N)=N/C(N)=NCCCCCCN=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1 YQMHOGGOFBFXQZ-ADZFUJRMSA-N 0.000 description 1
- YTPMCWYIRHLEGM-BQYQJAHWSA-N 1-[(e)-2-propylsulfonylethenyl]sulfonylpropane Chemical compound CCCS(=O)(=O)\C=C\S(=O)(=O)CCC YTPMCWYIRHLEGM-BQYQJAHWSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical group COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical group CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010009245 Clavicle fracture Diseases 0.000 description 1
- 101710200331 Cytochrome b-245 chaperone 1 Proteins 0.000 description 1
- 102100037186 Cytochrome b-245 chaperone 1 Human genes 0.000 description 1
- 101710119396 Cytochrome b-245 chaperone 1 homolog Proteins 0.000 description 1
- 241001505295 Eros Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000006893 Fetal Hypoxia Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010061308 Neonatal infection Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 206010056738 Uterine cervical laceration Diseases 0.000 description 1
- 206010046820 Uterine rupture Diseases 0.000 description 1
- 208000032160 Vaginal laceration Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009352 congenital transmission Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940092456 curosurf Drugs 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical group [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108010013480 succinylated gelatin Proteins 0.000 description 1
- 229940007079 succinylated gelatin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940080796 surfaxin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940063649 survanta Drugs 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、女性による経膣出産において潤滑剤として使用する、メタリン酸のアルカリ金属塩類を含まない組成物を製造するための、生理学的に許容される有機物質の使用に関する。その潤滑効果はこの場合、膣を経由して産道に本組成物を導入し、産道の実質的に全ての表面、又は産道表面の局部に層を形成することにより達成される。
− 分娩労力及び/又は分娩時間の低減
− 分娩痛の緩和
− 出産により母子に与える後遺症の低減
− 潤滑剤と抗微生物物質を組み合わせることによる、産褥感染及び新生児感染のリスクの低減
− 母親の産道の損傷(頸管裂傷、子宮裂傷、膣会陰裂傷、陰唇裂傷、外陰損傷)の回避及び/又は低減
− 骨盤底の損傷防止
− 尿失禁、便失禁及び生理学的障害の防止
− 会陰切開率の低減
− 介助経膣出産及び帝王切開率の低減及び/又は回避
− 会陰切開率の低減
− 麻酔の介入(局所、全身麻酔、鎮静剤、吸入麻酔)の低減及び/又は回避
− 分娩時胎児低酸素症の回避及び/又は低減
− 分娩時胎児仮死及び/又はその後遺症の回避及び/又は低減
− 鎖骨骨折、叢損傷又は脳出血等の分娩時の子の損傷の回避及び/又は低減
− 潤滑剤に肺界面活性剤様物質を組み合わせることによる新生児呼吸困難症候群の低減
− 細菌又はウイルス感染に関連する母子感染率の低減
Claims (8)
- 女性による経膣出産において潤滑剤として使用する、メタリン酸のアルカリ金属塩類を含まないゲルの形状である組成物を製造するための、生理学的に許容される有機物質の使用であって、当該有機物質が、セルロース;コラーゲン;ヒドロキシエチルセルロース、ヒドロキシプロピルセルロースから選択されるヒドロキシアルキルセルロース;カルボキシメチルセルロース及びそれらのアルカリ金属塩;セルロースアセテート;ヒドロキシエチルでんぷん、ヒドロキシプロピルでんぷんから選択されるヒドロキシアルキルでんぷん;ゼラチン;デキストラン及びヒドロキシアルキル化デキストラン;アルギン酸塩;ポリラクテート、ポリグリコレート、ポリソルベート及び対応するモノマーのコポリマーから選択されるヒドロキシカルボン酸のポリエステル;ポリブチレンカーボネートから選択される脂肪族ポリカーボネート;ポリエチレンオキシド、ポリプロピレンオキシド、ポリエチレンオキシド/ポリプロピレンオキシドコポリマーから選択されるポリアルキレンオキシド;ポリビニルアルコール並びにポリビニルピロリドン;ヒアルロン酸もしくはそのアルカリ金属塩;ポリ(メタ)アクリル酸;ポリ(メタ)アクリル酸アルキルエステル;ポリ(メタ)アクリル酸ヒドロキシアルキルエステル;ポリアクリルアミド;ポリビニルアセテートから選択されるポリビニルエステル;オレフィン/ビニルアセテートコポリマー;ポリウレタン;ポリアミド;ポリシロキサン;ジカルボン酸とジオールとのポリエステル;並びにポリエーテル;から選択される、天然、天然改質、又は合成のポリマーである、上記使用。
- 前記有機物質自体が前記組成物に潤滑効果をもたらす、又は前記有機物質が前記組成物の配合過程に潤滑効果を与えることを特徴とする、請求項1記載の使用。
- 前記潤滑効果を有する有機物質が、天然又は合成油、脂肪、及びワックスを含む、請求項2記載の使用。
- 前記有機物質が、前記組成物中に1〜99重量%の量で存在することを特徴とする、請求項1記載の使用。
- 前記有機物質が、さらに有効医薬成分、又は少なくとも2つの有効医薬成分の組み合わせを含むことを特徴とする、請求項1記載の使用。
- 有効医薬成分の量が、前記潤滑剤又は潤滑剤を含む前記配合に対し、0.0001〜10重量%であることを特徴とする、請求項5記載の使用。
- 前記有効医薬物質が、出産を抑制する、もしくは出産を促進する、痛みをやわらげる、感染を防止する、又は、新生児呼吸困難症候群を防止するために作用することを特徴とする、請求項5記載の使用。
- 生理学的に許容される有機潤滑剤を含むが、メタリン酸のアルカリ金属塩類を含まない、女性における経膣出産を容易にするためのゲルの形状である医薬組成物であって、当該生理学的に許容される有機潤滑剤が、セルロース;コラーゲン;ヒドロキシエチルセルロース、ヒドロキシプロピルセルロースから選択されるヒドロキシアルキルセルロース;カルボキシメチルセルロース及びそれらのアルカリ金属塩;セルロースアセテート;ヒドロキシエチルでんぷん、ヒドロキシプロピルでんぷんから選択されるヒドロキシアルキルでんぷん;ゼラチン;デキストラン及びヒドロキシアルキル化デキストラン;アルギン酸塩;ポリラクテート、ポリグリコレート、ポリソルベート及び対応するモノマーのコポリマーから選択されるヒドロキシカルボン酸のポリエステル;ポリブチレンカーボネートから選択される脂肪族ポリカーボネート;ポリエチレンオキシド、ポリプロピレンオキシド、ポリエチレンオキシド/ポリプロピレンオキシドコポリマーから選択されるポリアルキレンオキシド;ポリビニルアルコール並びにポリビニルピロリドン;ヒアルロン酸もしくはそのアルカリ金属塩;ポリ(メタ)アクリル酸;ポリ(メタ)アクリル酸アルキルエステル;ポリ(メタ)アクリル酸ヒドロキシアルキルエステル;ポリアクリルアミド;ポリビニルアセテートから選択されるポリビニルエステル;オレフィン/ビニルアセテートコポリマー;ポリウレタン;ポリアミド;ポリシロキサン;ジカルボン酸とジオールとのポリエステル;並びにポリエーテル;から選択される、天然、天然改質、又は合成のポリマーである、上記医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH00121/02A CH697081A5 (de) | 2002-01-22 | 2002-01-22 | Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten. |
CH0121/02 | 2002-01-22 | ||
PCT/EP2003/000548 WO2003066020A1 (de) | 2002-01-22 | 2003-01-21 | Zusammensetzung zur erleichterung der humangeburt |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005519071A JP2005519071A (ja) | 2005-06-30 |
JP2005519071A5 JP2005519071A5 (ja) | 2006-02-23 |
JP4846198B2 true JP4846198B2 (ja) | 2011-12-28 |
Family
ID=27671986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003565445A Expired - Fee Related JP4846198B2 (ja) | 2002-01-22 | 2003-01-21 | ヒトの出産を容易にするための組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050053670A1 (ja) |
EP (3) | EP1467707B1 (ja) |
JP (1) | JP4846198B2 (ja) |
AT (1) | ATE336228T1 (ja) |
AU (1) | AU2003229546A1 (ja) |
CA (1) | CA2477053C (ja) |
CH (1) | CH697081A5 (ja) |
CY (1) | CY1106227T1 (ja) |
DE (2) | DE50304651D1 (ja) |
DK (1) | DK1467707T3 (ja) |
ES (1) | ES2271572T3 (ja) |
PT (1) | PT1467707E (ja) |
WO (1) | WO2003066020A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
DE102004054552A1 (de) * | 2004-11-11 | 2006-05-18 | Hcb Happy Child Birth Holding Ag | Neue Zusammensetzung zur Erleichterung der Humangeburt |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
EP1886676A1 (en) * | 2006-08-09 | 2008-02-13 | Polichem S.A. | Compositions with enhanced elasticizing activity |
GB0620685D0 (en) * | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
CN107412885B (zh) * | 2014-01-13 | 2020-04-28 | 成都英诺新科技有限公司 | 一种助产用凝胶及其制备方法 |
WO2019059856A1 (en) | 2017-09-22 | 2019-03-28 | Turkuaz Sağlik Hi̇zmetleri̇ Medi̇kal Temi̇zli̇k Ki̇myasal Ürünler Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | OBSTETRIC GEL AND METHOD OF PRODUCTION |
WO2023148486A1 (en) * | 2022-02-01 | 2023-08-10 | Birthglide Limited | Birthing device |
GB2615312A (en) * | 2022-02-01 | 2023-08-09 | Birthglide Ltd | Birthing device |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267168A (en) * | 1977-03-11 | 1981-05-12 | Aquatain Partnership | Method of reducing bacteria on human tissue using liquid biocidal compositions comprising a mixture of silver ions and sodium pectate |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3496592A (en) | 1969-04-24 | 1970-02-24 | Judson O Jones | Portable apparatus for cleaning and partially drying carpets |
US3971848A (en) * | 1970-12-21 | 1976-07-27 | Kimitsu Chemical Laboratory Co. Ltd. | Lubricating composition for mucosa or epidermis |
JPS4948725B1 (ja) * | 1971-06-24 | 1974-12-23 | ||
US4184974A (en) * | 1974-05-16 | 1980-01-22 | Leuven James W Van | Liquid biocidal compositions comprising a mixture of silver ions and sodium pectate |
GB8323624D0 (en) * | 1983-09-02 | 1983-10-05 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
EP0163696B1 (en) * | 1983-11-14 | 1992-11-25 | Columbia Laboratories, Inc. | Use of a bioadhesive |
US4602623A (en) | 1983-12-30 | 1986-07-29 | Michael Cherkassky | Method of delivering a fetus |
GB8622698D0 (en) * | 1986-09-20 | 1986-10-29 | Smith & Nephew Ass | Dispenser |
US4859242A (en) * | 1987-03-16 | 1989-08-22 | Color Quest Inc. | Water soluble coloring compositions containing sparkle components |
US4981686A (en) * | 1987-05-18 | 1991-01-01 | Hardy Robert E | Personal lubricant |
GB8817015D0 (en) * | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
US5342617A (en) * | 1990-12-03 | 1994-08-30 | Medical Polymers, Inc. | Water-based human tissue lubricant |
JP3042546B2 (ja) * | 1991-04-23 | 2000-05-15 | 昭和電工株式会社 | 微粒子状の架橋型n−ビニルアミド樹脂及びミクロゲル、その製造法及び用途 |
YU66892A (sh) * | 1991-08-20 | 1995-10-24 | Hoechst Ag. | Fosfoinositolglikan - peptid sa delovanjem kao insulin |
NL9400160A (nl) * | 1994-02-02 | 1995-09-01 | Stichting Tech Wetenschapp | Therapeutische samenstelling voor het vervangen en/of aanvullen van lichaamsvloeistoffen. |
US5580574A (en) * | 1994-04-28 | 1996-12-03 | Hoffmann-La Roche Inc. | Pharmaceutical composition for transdermal delivery |
EP0851908B1 (en) * | 1995-06-07 | 2003-05-02 | Lee County Mosquito Control District | Lubricant compositions and methods |
DE19531893A1 (de) * | 1995-08-30 | 1997-03-06 | Bayer Ag | Juckreizmildernde, kosmetische und/oder pharmazeutische Zusammensetzungen |
US5885591A (en) * | 1996-07-02 | 1999-03-23 | Johnson & Johnson Consumer Products, Inc. | Personal lubricant compositions |
US5877209A (en) * | 1996-11-07 | 1999-03-02 | Yunis; Adel A. | Hair follicle protective formulations |
WO2000007603A2 (en) * | 1998-08-04 | 2000-02-17 | Madash Llp | End modified thermal responsive hydrogels |
US6139848A (en) * | 1999-02-12 | 2000-10-31 | Mcneil-Ppc, Inc. | Personal lubricant compositions |
RU2177789C2 (ru) | 1999-11-19 | 2002-01-10 | Общество с ограниченной ответственностью Научно-производственное предприятие "Тульская индустрия LTD" | Средство, способствующее созреванию шейки матки, способ ускорения созревания шейки матки и устройство для доставки лекарственного средства к шейке матки |
US20030114394A1 (en) * | 2001-10-29 | 2003-06-19 | Levine Howard L. | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
US7709026B2 (en) * | 2001-10-29 | 2010-05-04 | Columbia Laboratories, Inc. | Low concentration of peroxide for treating or preventing vaginal infections |
US7151091B2 (en) * | 2002-09-20 | 2006-12-19 | The Johns Hopkins University | Compositions and methods for preventing infection |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20050181057A1 (en) * | 2004-02-13 | 2005-08-18 | Rosenberg Paul K. | Vaginal lubricant |
-
2002
- 2002-01-22 CH CH00121/02A patent/CH697081A5/de not_active IP Right Cessation
-
2003
- 2003-01-21 ES ES03722326T patent/ES2271572T3/es not_active Expired - Lifetime
- 2003-01-21 EP EP03722326A patent/EP1467707B1/de not_active Expired - Lifetime
- 2003-01-21 PT PT03722326T patent/PT1467707E/pt unknown
- 2003-01-21 US US10/501,984 patent/US20050053670A1/en not_active Abandoned
- 2003-01-21 CA CA2477053A patent/CA2477053C/en not_active Expired - Fee Related
- 2003-01-21 DE DE50304651T patent/DE50304651D1/de not_active Expired - Lifetime
- 2003-01-21 AT AT03722326T patent/ATE336228T1/de active
- 2003-01-21 EP EP06007758A patent/EP1719502A1/de not_active Ceased
- 2003-01-21 DE DE20321512U patent/DE20321512U1/de not_active Expired - Lifetime
- 2003-01-21 DK DK03722326T patent/DK1467707T3/da active
- 2003-01-21 WO PCT/EP2003/000548 patent/WO2003066020A1/de active IP Right Grant
- 2003-01-21 EP EP10177089A patent/EP2255784A1/de not_active Ceased
- 2003-01-21 AU AU2003229546A patent/AU2003229546A1/en not_active Abandoned
- 2003-01-21 JP JP2003565445A patent/JP4846198B2/ja not_active Expired - Fee Related
-
2006
- 2006-11-01 CY CY20061101572T patent/CY1106227T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267168A (en) * | 1977-03-11 | 1981-05-12 | Aquatain Partnership | Method of reducing bacteria on human tissue using liquid biocidal compositions comprising a mixture of silver ions and sodium pectate |
Also Published As
Publication number | Publication date |
---|---|
ATE336228T1 (de) | 2006-09-15 |
DE50304651D1 (de) | 2006-09-28 |
EP1467707A1 (de) | 2004-10-20 |
EP2255784A1 (de) | 2010-12-01 |
EP1467707B1 (de) | 2006-08-16 |
US20050053670A1 (en) | 2005-03-10 |
DK1467707T3 (da) | 2006-12-27 |
CH697081A5 (de) | 2008-04-30 |
JP2005519071A (ja) | 2005-06-30 |
EP1719502A1 (de) | 2006-11-08 |
CY1106227T1 (el) | 2011-06-08 |
CA2477053A1 (en) | 2003-08-14 |
AU2003229546A1 (en) | 2003-09-02 |
PT1467707E (pt) | 2006-12-29 |
DE20321512U1 (de) | 2007-09-20 |
ES2271572T3 (es) | 2007-04-16 |
WO2003066020A1 (de) | 2003-08-14 |
CA2477053C (en) | 2012-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5641677B2 (ja) | ヒトの分娩を容易にするための新規組成物 | |
JP4846198B2 (ja) | ヒトの出産を容易にするための組成物 | |
WO2006089561A1 (en) | Pharmaceutical compositions containing organic acids useful for softening and ripening uterine cervix. | |
Ulmsten et al. | Intracervical versus intravaginal PGE 2 for induction of labor at term in patients with an unfavorable cervix | |
US20210260062A1 (en) | Treatment of Female Genital Schistosomiasis | |
Kafali et al. | Intrauterine lidocaine gel application for pain relief during and after hysterosalpingography | |
Adesiyun et al. | Clinical and investigative correlates of etiologic risk factors on treatment outcome of intrauterine adhesion in women with infertility: A descriptive study | |
Gorthey et al. | Vulvar condylomata acuminata complicating labor | |
Deliwala et al. | Therapeutic Efficacy of Misoprostol versus Ethacridine Lactate in Second Trimester Abortion–Randomised Controlled Study | |
Hsieh et al. | Conservative treatment of cervico-isthmic heterotopic pregnancy by fine needle aspiration for selective embryo reduction | |
Herabutya et al. | Mid‐trimester abortion using prostaglandin E2 gel | |
Pandya et al. | A rare case of cervical ectopic pregnancy | |
Khan et al. | MISSED ABORTION: MISOPROSTOL VERSUS CERVICAL CATHETER AS CERVICAL PRIMING AGENT | |
Ölmez et al. | Effect of misoprostol on cervical transition pain in office hysteroscopy: Results of a tertiary center | |
Sree Sudha et al. | Significant Risk Medical Devices–Obstetrics and Gynecology | |
Barqawi | Intrauterine fetal death: termination of pregnancy withintravaginal prostagladin E2 pessaries | |
Valentin et al. | Effect of a prostaglandin E1 analogue (gemeprost) on uterine and luteal circulation in normal first trimester pregnancies. A Doppler velocimetry study | |
Garg | Evaluation of Postpartum Blood Loss After Misoprostol-Induced and Oxytocin with Foley’s Catheter-Induced Labour: A Comparative Study | |
Irvine et al. | Efficacy of an intracervical prostaglandin E2 preparation, Cerviprost, on cervical ipening before first trimester abortion in bulliparous patients | |
Diawara et al. | Sonographic detection of unruptured dichorionic unilateral live twin ectopic pregnancy | |
VEENA et al. | EVALUATION OF PGE2 GEL FOR CERVICAL RIPENING AND INDUCfION OF LABOUR | |
Hutten-Czapski et al. | The occasional intrauterine contraceptive device insertion | |
Çetin et al. | Use of cervical dilators is not necessary during curettage after combined oral and vaginal administration of misoprostol from five to ten weeks of pregnancy | |
Methotrexate | Successful Treatment of a Cervical Pregnancy by Single Dose Methotrexate and Vaginal Misoprostol | |
Adoke et al. | Spontaneous fundal uterine rupture in a grandmultipara; an unusual site of rupture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090728 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091027 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091201 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091204 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101028 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110810 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110906 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111004 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111012 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |